Benitec Biopharma
BNTC
12 hedge funds and large institutions have $1.02M invested in Benitec Biopharma in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
158% more capital invested
Capital invested by funds: $395K → $1.02M (+$625K)
100% more funds holding
Funds holding: 6 → 12 (+6)
0.12% more ownership
Funds ownership: 0.33% → 0.45% (+0.12%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$316K |
| 2 |
Two Sigma Advisers
New York
|
+$194K |
| 3 |
Two Sigma Investments
New York
|
+$167K |
| 4 |
Renaissance Technologies
New York
|
+$148K |
| 5 |
VF
Virtu Financial
New York
|
+$55.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$75K |
| 2 |
Morgan Stanley
New York
|
-$63.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $324K | +$316K | +6,353 | New |
|
|
2
Two Sigma Advisers
New York
| $199K | +$194K | +3,897 | New |
|
|
3
Two Sigma Investments
New York
| $171K | +$167K | +3,361 | New |
|
|
4
Renaissance Technologies
New York
| $152K | +$148K | +2,980 | New |
|
|
VF
5
Virtu Financial
New York
| $57K | +$55.9K | +1,124 | New |
|
|
CS
6
Credit Suisse
Zurich,
Switzerland
| $47K | – | – | – |
|
|
7
Morgan Stanley
New York
| $39K | -$63.7K | -1,281 | -63% |
|
|
WAM
8
Warberg Asset Management
Winnetka,
Illinois
| $30K | +$29.2K | +588 | New |
|
9
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
RE
10
RBC Europe
London,
United Kingdom
| $18 | – | – | – |
|
|
SM
11
Sabby Management
Miami Beach,
Florida
| – | -$75K | -698 | Closed |
|
12
Wells Fargo
San Francisco,
California
| – | +$99 | +2 | New |
|
BNTC Hedge Fund Activity: Q4 2020 in Review
12 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2020, worth a combined $1.02M — up 158% from $395K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BNTC positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $316K. The largest seller was Sabby Management, exiting entirely with an estimated $75K sold.
- 12 institutional investors held Benitec Biopharma (BNTC) as of Q4 2020, up from 6 in Q3 2020.
- Funds reported $1.02M of Benitec Biopharma stock for Q4 2020, up 158% quarter-over-quarter.
- 7 funds opened new Benitec Biopharma positions in Q4 2020 and 1 closed out, a net change of +6 holders.
- The largest Benitec Biopharma buyer in Q4 2020 was Hudson Bay Capital Management, an estimated $316K added.
- The largest Benitec Biopharma seller in Q4 2020 was Sabby Management, an estimated $75K sold.
Based on aggregated 13F filings for Q4 2020.